ABSTRACTS OF THE 21st ANNUAL MEETING OF THE ITALIAN ...

Abstracts of the 21st Annual Meeting of the Italian Society of Uro-Oncology (SIUrO), 22-24 June, 2011, Naples, Italy
leiomyomas appear to be composed of fusocellular elements,
showing absence of mitotic figures, pleomorphism,
hyperchromatism and, above all, with an absence of
perilesional invasion. Finally, despite the diagnostic
difficulties, the gold standard of therapy is still surgery.
142
LOCALIZED PROSTATE CANCER TREATED
WITH THREE-DIMENSIONAL CONFORMAL
RADIATION THERAPY (3D-CRT):
A SINGLE INSTITUTION EXPERIENCE
Girolamo Spagnoletti, Rita Marchese, Anna Maria Leo,
Grazia Nardella, Vincenzo Oriolo and Giuseppe Bove
Radiotherapy Department, Foggia University Hospital, Italy
Background and Aim: Three-dimensional conformal radiation
therapy (3D-CRT) is often used as a curative treatment for
clinically localized prostate cancer. Development of
sophisticated imaging modalities, coupled with irradiation
treatment planning technologies, allows for precise
localization of the prostate gland and other target tissues with
respect to the treatment beam (1). The aim of this study was to
assess the benefit and the toxicity of 3D-CRT for the treatment
of localized prostate cancer. Patients and Methods: We
retrospectively reviewed the cases of 222 men treated with
3D-CRT at the Radiotherapy Department of Foggia from 2006
to 2009. Forty patients were lost to follow-up and our analysis
thus included 182 patients treated for localized prostate cancer.
The median age was 75 (range: 55-89) years. All patients
underwent biopsy and analysis of histological specimens
showed adenocarcinoma, with a median Gleason score of 7.
Median pre-radiotherapy PSA was 11 ng/ml. Clinical tumor
stage was T1 for 18 patients, T2 for 159 patients and T3 for 5
patients. Hormonal therapy was prescribed for 148 (81.3%)
patients and they all received hormonal therapy before starting
radiotherapy. Fifty-five (30%) patients also received pelvic
radiotherapy according to the Roach formula, with a median
dose of 44 Gy to pelvic nodes, while the total median dose to
the prostate gland was 73.8 Gy. Toxicity was assessed with
RTOG scale. Biochemical failure rate, disease-free survival
(DFS) and overall survival (OS) were calculated. Results: The
median follow-up was 28 months. Radiotherapy was welltolerated
and all patients received the prescribed dose. Acute
toxicity included rectal (G0, 89%; G1, 11%; G2, 0%) and
urinary events (G0, 80.8%; G1, 13.7%; G2, 5.5%). Late
toxicity included rectal (G0, 93.9%; G1, 5.5%; G2, 0.6%) and
urinary events (G0, 93.4%; G1, 6.6%; G2, 0%). Three patients
(1.6%) experienced biochemical failure after radiotherapy and
one patient had bone metastasis. Three-year OS and DFS were
94.5% and 89%, respectively. Five-year OS and DFS were
91% and 85%, respectively. Discussion and Conclusion: Our
retrospective analysis showed good results in terms of OS and
DFS, with very low acute and late toxicities. 3D-CRT should
be considered as a valid option for treatment of prostate cancer
patients, since it is a safe and well-tolerated treatment.
1 Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon
O, Park J and Shippy A: Long-term results of conformal
radiotherapy for prostate cancer: impact of dose escalation
on biochemical tumor control and distant metastases-free
survival outcomes. Int J Radiat Oncol Biol Phys 71(4):
1028-1033, 2008.
143
TOXICITY AND HEALTH-RELATED QUALITY OF
LIFE IN ELDERLY PROSTATE CANCER PATIENTS
TREATED WITH RADIOTHERAPY
Andrea Ballaré 1 , Barbara Cannillo 2 , Maria Bassi 1 ,
Danilo Minocci 3 , Gloria Maso 3 , Paola Fedeli 4
and Anna Maria Foscolo 5
Departments of 1Radiotherapy, 4Oncology and
5Anatomopathology, Castelli Hospital ASL VCO,
Verbania (VCO), Italy;
2Department of Medical Physics, Maggiore
della Carità University Hospital, Novara, Italy;
3Department of Urology, San Biagio Hospital ASL VCO,
Domodossola, Italy
Background and Aim: Adjuvant radiotherapy has been
associated with improved freedom from biochemical failure as
compared with radical prostatectomy alone and it is often
delivered after surgery for high-risk patients (1, 2). The aim
of this study was to assess the benefit and the toxicity of
postoperative radiotherapy after surgery for prostate cancer.
Patients and Methods: We retrospectively analyzed the cases
of 80 men treated with adjuvant radiotherapy at the
radiotherapy department of Foggia Hospital from 2006 to
2009. All patients underwent radical prostatectomy and pelvic
lymphadenectomy. The median age was 65 (range: 43-77)
years. Analysis of histological specimens showed positive
margins in 68 patients (85%), extracapsular spread in 50
patients (62.5%) and nodal involvement in 2 patients (2.5%).
Median pre-surgery PSA was 9.5 ng/ml and median Gleason
score was 7. Hormonal therapy was prescribed for 51 patients
(63.7%), of whom 28 (55%) received total androgen
deprivation and 23 (45%) received bicalutamide alone (150
mg/day). Radiotherapy was delivered with a median dose of
68 Gy (2 Gy/day). Disease-free survival (DFS) and overall
survival (OS) were calculated and toxicity was assessed with
RTOG scale. Results: The median follow-up was 25 months.
The median PSA value after adjuvant radiotherapy was 0.07
ng/ml. Radiotherapy was well-tolerated; only one patient
1885